A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
View / Open Files
Authors
Batra, Ankita Sati
Callari, Maurizio
Batra, Rajbir Nath
Pogrebniak, Katherine
Sandoval, Jose
Cassidy, John W
Tufegdzic-Vidakovic, Ana
Jones, Linda
Provenzano, Elena
Eirew, Peter
Hadfield, James
McLaren-Douglas, Anne
Barthorpe, Andrew
Lightfoot, Howard
O’Connor, Mark J
Gray, Joe
Cortes, Javier
Baselga, Jose
Marangoni, Elisabetta
Welm, Alana L
Aparicio, Samuel
Serra, Violeta
Garnett, Mathew J
Publication Date
2016-09-22Journal Title
Cell
ISSN
0092-8674
Publisher
Elsevier
Volume
167
Pages
260-274
Language
English
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Bruna, A., Rueda Palacio, O., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., Pogrebniak, K., et al. (2016). A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 167 260-274. https://doi.org/10.1016/j.cell.2016.08.041
Abstract
The inter- and intra-tumor heterogeneity of breast
cancer needs to be adequately captured in pre-clinical
models. We have created a large collection of
breast cancer patient-derived tumor xenografts
(PDTXs), in which the morphological and molecular
characteristics of the originating tumor are preserved
through passaging in the mouse. An integrated platform
combining in vivo maintenance of these PDTXs
along with short-term cultures of PDTX-derived tumor
cells (PDTCs) was optimized. Remarkably, the
intra-tumor genomic clonal architecture present in
the originating breast cancers was mostly preserved
upon serial passaging in xenografts and in shortterm
cultured PDTCs. We assessed drug responses
in PDTCs on a high-throughput platform and validated
several ex vivo responses in vivo. The biobank
represents a powerful resource for pre-clinical breast
cancer pharmacogenomic studies (http://caldaslab.
cruk.cam.ac.uk/bcape), including identification of
biomarkers of response or resistance.
Sponsorship
This research was supported with funding from Cancer Research UK and from
the European Union to the EUROCAN Network of Excellence (FP7; grant numnumber
260791). M.C. has received funding from the European Union’s Horizon
2020 research and innovation program under the Marie Sk1odowska-Curie
grant agreement no. 660060 and was supported by the Department of Experimental
Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan, Italy. R.N.B. is supported by the Wellcome Trust PhD
Programme in Mathematical Genomics and Medicine. S-J.S. is supported
by the Wellcome Trust PhD Programme for Clinicians in Cambridge. A.Bruna,
O.M.R., E.M., V.S., and C.C. are members of the EurOPDX Consortium. Weare
very grateful for the generosity of all the patients that donated samples for implantation.
We are also deeply indebted to all the staff (surgeons, pathologists,
oncologists, theatre staff, and other ancillary personnel) at the Cambridge
Breast Unit, Cambridge University Hospital NHS Foundation Trust, for facilitating
the timely collection of samples. We thank the Cancer Research UK
Cambridge Institute Genomics, Bioinformatics, Histopathology, Flow Cytometry,
Biological Resource, and Bio-repository Core Facilities for support during
the execution of this project.
Funder references
European Commission FP7 Network of Excellence (NoE) (260791)
EC FP7 NOE (260791)
Cancer Research UK (CB4140)
Cancer Research UK (unknown)
Cancer Research UK (unknown)
Cancer Research UK (60098573)
Cancer Research UK (unknown)
WELLCOME TRUST (106566/Z/14/Z)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0515-10090)
Department of Health (via National Institute for Health Research (NIHR)) (unknown)
Cambridge University Hospitals NHS Foundation Trust (CUH) (RG51913)
Cancer Research UK (A15580)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Cancer Research UK (16465)
Academy of Medical Sciences (unknown)
MEDICAL RESEARCH COUNCIL (MR/M008975/1)
Academy of Medical Sciences (ALI 01/08/14)
Pathological Society of Great Britain & Ireland (CDF 2012/01)
European Commission FP7 Collaborative projects (CP) (258967)
Cancer Research UK (C507/A16278)
EC FP7 CP (258967)
Cancer Research UK (20544)
MRC (MR/P012442/1)
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (115749)
EC FP7 CP (242006)
ECH2020 EUROPEAN RESEARCH COUNCIL (ERC) (694620)
Cancer Research UK (A24622)
Cancer Research UK (C14303_do not transfer)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (660060)
Identifiers
External DOI: https://doi.org/10.1016/j.cell.2016.08.041
This record's URL: https://www.repository.cam.ac.uk/handle/1810/260853
Rights
Attribution 4.0 International, Attribution 4.0 International, Attribution 4.0 International, Attribution 4.0 International
Recommended or similar items
The following licence files are associated with this item: